TherapeuticsMD, Inc.
Business
TherapeuticsMD, Inc. is a pharmaceutical royalty company that receives royalties on women's healthcare products licensed to third-party commercialization partners. The company's licensed portfolio includes IMVEXXY (vaginal estradiol inserts for dyspareunia), BIJUVA (bioidentical estradiol-progesterone capsules for vasomotor symptoms), ANNOVERA (contraceptive vaginal system), and prenatal vitamin products. Revenue is generated through tiered royalties and minimum annual payments from Mayne Pharma in the United States and from Knight Therapeutics and Theramex for international markets outside the U.S.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| License revenue | 3 | 2 | — | — | — | |
| General and administrative | 7 | 6 | 9 | 57 | 81 | |
| Write-off and impairment of patents | 176,000 | 1 | — | — | — | |
| Depreciation & amortization | 384,000 | 509,000 | 922,000 | 1 | — | |
| Total operating expenses | 7 | 8 | 10 | 67 | 81 | |
| Loss from operations | −4 | −6 | −9 | 1 | −80 | |
| Interest income, net | 142,000 | 135,000 | — | — | — | |
| Sublease income | 2 | 1 | — | — | — | |
| Miscellaneous income | 2 | 2 | 781,000 | — | — | |
| Total other income | 4 | 4 | 781,000 | −117,000 | 272,000 | |
| Loss from continuing operations before income taxes | −653,000 | −2 | −8 | 1 | −79 | |
| Income tax benefit | — | 31,000 | 43,000 | — | — | |
| Net loss from continuing operations | −653,000 | −2 | −8 | 1 | −79 | |
| Income from discontinued operations, net of income taxes | 84,000 | 131,000 | −3 | 111 | — | |
| Net loss | −569,000 | −2 | −10 | 112 | −172 | |
| Continuing operations (in Dollars per share) | −0.06 | −0.2 | −0.74 | 0.12 | −9.96 | |
| Discontinued operations, net (in Dollars per share) | 0.01 | 0.01 | −0.25 | 12.29 | −11.7 | |
| Net loss per common share, basic (in Dollars per share) | −0.05 | −0.19 | −0.99 | 12.41 | −21.66 | |
| Continuing operations (in Dollars per share) | −0.06 | −0.2 | −0.74 | 0.11 | −9.96 | |
| Discontinued operations, net (in Dollars per share) | 0.01 | 0.01 | −0.25 | 11.84 | −11.7 | |
| Net loss per common share, diluted (in Dollars per share) | −0.05 | −0.19 | −0.99 | 11.96 | −21.66 | |
| Weighted average common shares, basic (in Shares) | 12 | 12 | 10,441 | 9 | 8 | |
| Weighted average common shares, diluted (in Shares) | 12 | 12 | 10,441 | 9 | 8 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 5 | — | — | — | |
| Royalty receivable, current portion | 4 | 4 | 3 | — | — | |
| Prepaid and other current assets | 3 | 4 | 4 | 6 | 6 | |
| Total current assets | 14 | 12 | 12 | 55 | 119 | |
| License rights and other intangible assets, net | 4 | 4 | 6 | 7 | 7 | |
| Right of use assets, net | 5 | 6 | 7 | 8 | 8 | |
| Royalty receivable, long term | 14 | 16 | 18 | 20 | — | |
| Other non-current assets | 444,000 | 130,000 | 58,000 | 253,000 | 253,000 | |
| Total assets | 38 | 39 | 43 | 90 | 169 | |
| Accounts payable | 377,000 | 258,000 | 27,000 | 2 | 3 | |
| Accrued expenses and other current liabilities | 2 | 2 | 3 | — | — | |
| Current liabilities of discontinued operations | 3 | 3 | 4 | 26 | 48 | |
| Total current liabilities | 5 | 5 | 7 | 47 | 253 | |
| Operating lease liabilities | 5 | 6 | 7 | 7 | 8 | |
| Other non-current liabilities | 873,000 | 744,000 | 636,000 | 1 | 2 | |
| Total liabilities | 11 | 11 | 14 | 55 | 263 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Common stock, par value $0.001; 32,000 and 32,000 shares authorized, 11,574 and 11,532 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 11,000 | 11,000 | 11,000 | 9,000 | 9,000 | |
| Additional paid-in capital | 979 | 979 | 979 | 974 | 958 | |
| Accumulated deficit | −952 | −952 | −950 | −939 | −1,051 | |
| Total stockholders equity | 27 | 27 | 29 | 35 | −94 | |
| Total liabilities and stockholders equity | 38 | 39 | 43 | 90 | 169 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Write-off and impairment of patents | 176,000 | 1 | — | — | — | |
| Share-based payment compensation costs | 75,000 | 264,000 | 1 | 12 | 18 | |
| Amortization of right of use assets | 809,000 | 771,000 | — | — | — | |
| Prepaid and other current assets | 201,000 | 397,000 | 2 | 620,000 | −1 | |
| Other assets | 2 | 2 | −1 | — | — | |
| Accounts payable | 119,000 | 231,000 | −2 | −1 | −1 | |
| Accrued expenses and other current liabilities | 272,000 | −1 | −16 | 4 | 5 | |
| Lease liabilities | −1 | −990,000 | — | — | — | |
| Other non-current liabilities | 129,000 | 108,000 | −471,000 | −121,000 | 2 | |
| Total adjustments | 3 | 3 | −15 | 8 | 24 | |
| Net cash provided by continuing operating activities | 2 | 1 | −23 | 9 | −55 | |
| Net cash used in operating activities | −30,000 | −438,000 | −25 | −13 | −88 | |
| Net cash used in discontinued operations | −30,000 | −438,000 | −25 | 210 | −88 | |
| Net increase in cash | 2 | 732,000 | −45 | −16 | −15 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is TherapeuticsMD, Inc.'s CIK number?
TherapeuticsMD, Inc.'s SEC CIK number is 0000025743 (25743). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find TherapeuticsMD, Inc.'s SEC filings?
All of TherapeuticsMD, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did TherapeuticsMD, Inc. last report earnings?
TherapeuticsMD, Inc. (TXMD) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-055070). This is TherapeuticsMD, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is TherapeuticsMD, Inc.'s most recent earnings 8-K?
TherapeuticsMD, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001213900-26-055070. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View TherapeuticsMD, Inc.'s latest earnings 8-K →
Look up any company's CIK number →